| Jun 25 |
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
|
| Jun 24 |
7 Biotech Stocks to Buy on the Dip: June 2024
|
| Jun 24 |
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
|
| Jun 21 |
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
|
| Jun 21 |
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
|
| Jun 18 |
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
|
| Jun 18 |
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|
| Jun 17 |
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
|
| Jun 12 |
Regenxbio CEO to step down after 15 years
|
| Jun 12 |
REGENXBIO names new chief executive
|
